Bridgewater Associates LP Cuts Holdings in Phreesia, Inc. (NYSE:PHR)

Bridgewater Associates LP lessened its position in Phreesia, Inc. (NYSE:PHR - Free Report) by 70.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,971 shares of the company's stock after selling 21,474 shares during the period. Bridgewater Associates LP's holdings in Phreesia were worth $226,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in PHR. State Street Corp lifted its position in Phreesia by 7.1% in the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company's stock valued at $30,256,000 after acquiring an additional 88,517 shares in the last quarter. Barclays PLC lifted its holdings in shares of Phreesia by 83.6% during the third quarter. Barclays PLC now owns 94,929 shares of the company's stock valued at $2,163,000 after purchasing an additional 43,225 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Phreesia by 4.7% during the third quarter. Geode Capital Management LLC now owns 1,245,797 shares of the company's stock valued at $28,397,000 after buying an additional 55,934 shares during the last quarter. Franklin Resources Inc. increased its holdings in Phreesia by 3.0% in the 3rd quarter. Franklin Resources Inc. now owns 1,497,631 shares of the company's stock worth $31,495,000 after buying an additional 42,973 shares in the last quarter. Finally, Wesbanco Bank Inc. raised its position in Phreesia by 76.9% in the 4th quarter. Wesbanco Bank Inc. now owns 46,000 shares of the company's stock worth $1,157,000 after buying an additional 20,000 shares during the last quarter. Hedge funds and other institutional investors own 92.10% of the company's stock.

Phreesia Stock Performance

Shares of PHR stock traded up $0.14 during trading hours on Friday, reaching $24.73. 268,854 shares of the company traded hands, compared to its average volume of 432,544. The firm has a 50-day moving average price of $25.51 and a 200 day moving average price of $24.37. The company has a market cap of $1.45 billion, a P/E ratio of -16.82 and a beta of 0.82. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $30.53.

Insiders Place Their Bets

In other news, General Counsel Allison C. Hoffman sold 1,213 shares of the business's stock in a transaction dated Wednesday, April 16th. The stock was sold at an average price of $23.81, for a total value of $28,881.53. Following the transaction, the general counsel now directly owns 137,921 shares in the company, valued at $3,283,899.01. The trade was a 0.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Evan Roberts sold 3,519 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $30.06, for a total value of $105,781.14. Following the sale, the chief operating officer now owns 741,197 shares of the company's stock, valued at $22,280,381.82. This represents a 0.47 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 146,930 shares of company stock worth $4,067,102. Company insiders own 5.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. KeyCorp reduced their price target on shares of Phreesia from $30.00 to $28.00 and set an "overweight" rating for the company in a research note on Wednesday, April 16th. Royal Bank of Canada raised shares of Phreesia from a "sector perform" rating to an "outperform" rating and lifted their target price for the stock from $24.00 to $32.00 in a research report on Wednesday, January 8th. Citigroup increased their price target on Phreesia from $31.00 to $35.00 and gave the company a "buy" rating in a report on Friday, January 10th. DA Davidson cut their price objective on Phreesia from $36.00 to $34.00 and set a "buy" rating for the company in a report on Monday, April 14th. Finally, Piper Sandler reissued an "overweight" rating and issued a $33.00 target price (up previously from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat, Phreesia has a consensus rating of "Buy" and a consensus target price of $31.33.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.